Mouse & Rat
Monoclonal Antibodies
BIOTEM ‘s expertise and know-how are internationally recognised. The efficient generation of monoclonal antibodies requires to strategically master two crucial stages:
The company masters a wide range of technologies which allows the achievement of highly challenging projects.
For each project, our team carries out the most relevant screening strategy to identify the desired hybridomas / antibodies (with reduced risks of generating false positive and false negative results).
HybridoMap
Preliminary
phase
For each project, we define together with our clients very precise specifications based on:
Definition of
specifications
Results guaranteed
by BIOTEM
Definition of the most
relevant strategy
Target typology:
- Post-translational modifications (phosphorylation, nitration, glycosylation)
- Intra or extra-cellular proteins
- Membrane proteins (GPCR, ion channels, etc.)
- Peptides
- Nucleic acids
- Cellular antigens (cells, virus, bacteria)
- Chemical compounds (haptens)
End applications:
- ELISA, WB, IP, IF, IHC, FACS
- Functional tests...
Starting materials & project
restrictions:
- Material available (quantity / purity)
- Immunogenicity
- Toxicity
- Specificity / Cross reactions
- Deadline
Peptide
design
Immunisation with peptides is a relevant strategy for the generation of antibodies directed against selected epitopes.
This approach also reduces the need for sophisticated protein preparations for immunisation.
In order to obtain full project success, all the key parameters of peptide design must be taken into account:
- Application (WB, ELISA, IP, IHC...)
- Specificity (wanted /
unwanted
cross
reactions) - Epitope prediction and analysis (different algorithms)
- Conjugation strategy
Membrane
proteins
BIOTEM has tailored solutions for the production of membrane immunogens (GPCR, ion channels...).
Starting with a sequence and/or a plasmid cDNA, the target proteins can be obtained by exclusive methods in the purified form as part of proteo-liposomes and/or as soluble proteins.
- Conformational and functional proteins (quality controls, Patch Clamp, functional test...)
- Generation of antibodies against native epitopes
- Compatible with all immunisation protocols (R.A.D® protocol, subtractive...)
Immunisation
fusion
BIOTEM provides a highly efficient service for the custom generation of monoclonal antibodies. Different protocols can be implemented individually or in combination.
R.A.D ®
Protocol
Exclusive to BIOTEM
This exclusive method allows the fast development of hybridomas in less than a month (immunisation, fusion and screening included).
The R.A.D ® protocol therefore enables us to shorten by up to 3 months the duration of complete projects (including the stages of cloning and the production/purification of antibodies).
Substractive
Immunisation
BIOTEM masters various subtractive immunisation methods.
These techniques are particularly useful for the generation of antibodies against epitopes that are poorly immunogenic and/or sharing a high degree of homology.
Genetic
Immunisation
The genetic immunisation is based on the in vivo production of an immunogenic protein expressed from a plasmid DNA.
This method enables us to rapidly obtain specific antibodies starting from a DNA sequence.
BIOTEM offers its expertise and know-how for the evaluation and implementation of any genetic immunisation project.
in vitro immunisation / re-stimulation
The injection of an immunising agent isn’t always the most pertinent approach to develop monoclonal antibodies.
Some molecules are indeed very toxic after injection and/or not immunogenic.
In order to circumvent some of the inherent problems with in vivo immunisation, BIOTEM can propose alternative solutions based on in vitro immunisation protocols.
Screening
Cloning
The development of monoclonal antibodies includes several key screening stages:
Exclusive to BIOTEM
The Cyclop Screening System is a unique technical platform coupled with a LIMS (Laboratory Information Management System).
This proprietary technology ensures an optimal management of the complete monoclonal antibody project phases:
Microplate handling and fluidic transfers
Screening robustness
Unparalleled traceability of the clones
- Primary screening
of hybridomas from the fusion
(polyclonal phase) - Confirmation
test of positive hybridomas
(polyclonal phase) - Cloning
of hybridomas
(monoclonal cell line)
During these stages, BIOTEM implements an optimised project management:
Antibody
Productions, Purifications
& Modifications
HyperFlask production, CELLine, Bioreactors, Ascites, Ion exchange chromatography , Affinity, Size exclusion, Antibody precipitation, Hydrophobic interactions, Papain, learn more...
